Levamisole: Clinical Applications and Evidence-Based Recommendations
Primary Indication in Humans
Levamisole is no longer recommended for routine clinical use in humans. While historically used as an anthelmintic for intestinal worms and as adjuvant therapy for colon cancer, current evidence does not support its continued use in either indication.
Intestinal Helminth Infections
Historical Use
Levamisole was previously considered a drug of choice for ascariasis, with single doses of 50-150 mg eliminating parasites in 90-100% of patients 1. It demonstrated activity against hookworms but had minimal efficacy against whipworms, pinworms, and Strongyloides 1.
Current Status
Levamisole is NOT approved for human use as an anthelmintic. The FDA-approved formulations are exclusively for veterinary use in cattle and sheep 2. For human intestinal helminth infections, including Ascaris lumbricoides, albendazole (400 mg single oral dose) is the current standard of care 3.
Critical Caveat: The available levamisole products are veterinary formulations and explicitly state "NOT FOR USE IN HUMANS" 2. Using these products in humans would be inappropriate and potentially dangerous.
Adjuvant Therapy for Colon Cancer
Historical Evidence
In the 1990s, levamisole combined with fluorouracil (5-FU) showed promise for Stage III (Dukes C) colon cancer:
- The landmark 1990 trial demonstrated 41% reduction in recurrence risk and 33% reduction in death rate with 5-FU plus levamisole versus observation 4
- The 1995 follow-up confirmed these benefits with median 6.5-year follow-up 5
- Historical dosing: levamisole 50 mg orally three times daily for 3 days, repeated every 2 weeks for 1 year, combined with 5-FU 4, 5
Current Evidence Against Use
Levamisole should NOT be used in colon cancer treatment today. The evidence has evolved significantly:
- A 2003 randomized trial directly comparing 5-FU/levamisole versus 5-FU alone found no advantage for the combination in disease-free survival or overall survival, while toxicity (leukopenia and hepatic toxicity) was significantly increased with levamisole 6
- The 2004 ASCO guidelines for Stage II colon cancer do not recommend levamisole, focusing instead on 5-FU-based regimens without levamisole 7
- Modern adjuvant therapy has moved to more effective regimens (FOLFOX, CAPOX) that do not include levamisole
Stage-Specific Recommendations
Stage III (Node-Positive) Colon Cancer:
- Use modern combination chemotherapy (FOLFOX or CAPOX)
- Levamisole is obsolete and offers no benefit over 5-FU alone 6
Stage II (Node-Negative) Colon Cancer:
- Routine adjuvant chemotherapy is not recommended 7
- Consider chemotherapy only for high-risk features: inadequately sampled nodes, T4 lesions, perforation, or poorly differentiated histology 7
- When treatment is indicated, use modern 5-FU-based regimens without levamisole
Toxicity Profile
When levamisole was used historically, adverse effects included:
- Common: Nausea, vomiting, abdominal pain, metallic taste, flu-like symptoms, dizziness 8
- Serious: Granulocytopenia/leukopenia (most concerning) 6, 8
- Hepatic toxicity: Significantly increased when combined with 5-FU 6
Clinical Bottom Line
Levamisole has no role in modern clinical practice:
- For intestinal helminths: Use albendazole or mebendazole; levamisole is only available as veterinary formulation 2, 3
- For colon cancer: Use contemporary regimens (FOLFOX, CAPOX); levamisole adds toxicity without benefit 6
The drug represents an important historical milestone in oncology but has been superseded by safer, more effective alternatives in both parasitology and oncology.